Becton, Dickinson and Company (NYSE:BDX) Shares Sold by First American Bank

First American Bank decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 4.0% in the 3rd quarter, Holdings Channel reports. The fund owned 6,520 shares of the medical instruments supplier’s stock after selling 269 shares during the period. First American Bank’s holdings in Becton, Dickinson and Company were worth $1,572,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Livelsberger Financial Advisory acquired a new stake in Becton, Dickinson and Company in the third quarter valued at approximately $26,000. Sound Income Strategies LLC grew its position in shares of Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares in the last quarter. Opal Wealth Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company during the second quarter worth approximately $45,000. Abound Wealth Management grew its position in shares of Becton, Dickinson and Company by 96.0% during the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after buying an additional 96 shares in the last quarter. Finally, Chilton Capital Management LLC grew its position in shares of Becton, Dickinson and Company by 1,233.3% during the second quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 185 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $238.13 on Monday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. The stock has a market capitalization of $68.82 billion, a PE ratio of 52.45, a price-to-earnings-growth ratio of 1.79 and a beta of 0.42. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $259.92. The business’s fifty day moving average price is $237.46 and its 200 day moving average price is $235.04.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The company had revenue of $4.99 billion for the quarter, compared to analysts’ expectations of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period last year, the business posted $2.96 earnings per share. Equities research analysts forecast that Becton, Dickinson and Company will post 13.11 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on BDX shares. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price target for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Stifel Nicolaus raised their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Evercore ISI raised their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Finally, Raymond James reduced their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, Becton, Dickinson and Company currently has an average rating of “Buy” and a consensus target price of $282.63.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.